CA2493859C - Preventive/remedy for arteriosclerosis comprising adiponectin - Google Patents

Preventive/remedy for arteriosclerosis comprising adiponectin Download PDF

Info

Publication number
CA2493859C
CA2493859C CA2493859A CA2493859A CA2493859C CA 2493859 C CA2493859 C CA 2493859C CA 2493859 A CA2493859 A CA 2493859A CA 2493859 A CA2493859 A CA 2493859A CA 2493859 C CA2493859 C CA 2493859C
Authority
CA
Canada
Prior art keywords
adiponectin
mice
deficient
arteriosclerosis
mouse
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2493859A
Other languages
English (en)
French (fr)
Other versions
CA2493859A1 (en
Inventor
Takashi Kadowaki
Toshimasa Yamauchi
Naoto Kubota
Yasuo Terauchi
Tetsuya Kubota
Tetsuo Noda
Ryozo Nagai
Yasushi Imai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Japan Science and Technology Agency
Original Assignee
Japan Science and Technology Agency
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Science and Technology Agency filed Critical Japan Science and Technology Agency
Publication of CA2493859A1 publication Critical patent/CA2493859A1/en
Application granted granted Critical
Publication of CA2493859C publication Critical patent/CA2493859C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2493859A 2002-05-24 2003-05-26 Preventive/remedy for arteriosclerosis comprising adiponectin Expired - Fee Related CA2493859C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2002/151220 2002-05-24
JP2002151220 2002-05-24
PCT/JP2003/006518 WO2003099319A1 (en) 2002-05-24 2003-05-26 Preventive/remedy for arteriosclerosis

Publications (2)

Publication Number Publication Date
CA2493859A1 CA2493859A1 (en) 2003-12-04
CA2493859C true CA2493859C (en) 2012-05-15

Family

ID=29561246

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2493859A Expired - Fee Related CA2493859C (en) 2002-05-24 2003-05-26 Preventive/remedy for arteriosclerosis comprising adiponectin

Country Status (7)

Country Link
US (2) US7419955B2 (de)
EP (1) EP1537875B1 (de)
JP (1) JP4147220B2 (de)
AU (1) AU2003234845A1 (de)
CA (1) CA2493859C (de)
DE (1) DE60329000D1 (de)
WO (1) WO2003099319A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2003063894A1 (ja) * 2002-01-31 2005-05-26 独立行政法人科学技術振興機構 インスリン抵抗性改善剤
JP2003339272A (ja) * 2002-05-24 2003-12-02 Japan Science & Technology Corp アディポネクチン遺伝子欠損非ヒト動物
GB0312122D0 (en) * 2003-05-27 2003-07-02 Pharmagene Lab Ltd Therapeutic method
JP2007031302A (ja) * 2005-07-25 2007-02-08 Noevir Co Ltd アディポネクチン産生促進剤、及び代謝異常症候群予防剤
JP2007223985A (ja) * 2006-02-27 2007-09-06 Tokyo Univ Of Marine Science & Technology 脂肪吸収抑制剤、脂肪吸収抑制作用を有する健康食品及び脂肪吸収抑制作用を有するペットフード
US20080231557A1 (en) * 2007-03-20 2008-09-25 Leadis Technology, Inc. Emission control in aged active matrix oled display using voltage ratio or current ratio
TW201014598A (en) * 2008-08-27 2010-04-16 Otsuka Pharma Co Ltd Agent for treating pulmonary disease
JP5685086B2 (ja) 2009-01-29 2015-03-18 ホクサン株式会社 アディポネクチンを含有する経口用摂食調整剤
JP2019205355A (ja) * 2016-09-30 2019-12-05 国立大学法人名古屋大学 分子改変体アディポネクチン及び分子改変体アディポネクチンを含む医薬組成物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2767135B1 (fr) * 1997-08-06 2002-07-12 Genset Sa Recepteur complexe lsr, activite, clonage, et application au diagnostic, a la prevention et/ou au traitement de d'obesite et des risques ou complications associes
JP3538711B2 (ja) * 1997-10-29 2004-06-14 大塚製薬株式会社 平滑筋増殖抑制組成物、動脈硬化症診断方法及びそのキット
US6566332B2 (en) * 2000-01-14 2003-05-20 Genset S.A. OBG3 globular head and uses thereof for decreasing body mass
EP1365022A4 (de) 2001-02-01 2004-04-28 Mochida Pharm Co Ltd Adiponectin-assoziiertes protein

Also Published As

Publication number Publication date
JPWO2003099319A1 (ja) 2005-09-22
EP1537875A4 (de) 2008-04-23
US20090239938A1 (en) 2009-09-24
JP4147220B2 (ja) 2008-09-10
DE60329000D1 (de) 2009-10-08
EP1537875B1 (de) 2009-08-26
US20060166873A1 (en) 2006-07-27
EP1537875A1 (de) 2005-06-08
US7419955B2 (en) 2008-09-02
WO2003099319A1 (en) 2003-12-04
CA2493859A1 (en) 2003-12-04
AU2003234845A1 (en) 2003-12-12

Similar Documents

Publication Publication Date Title
US20090239938A1 (en) Preventive/remedy for arteriosclerosis
Shalev Minireview: thioredoxin-interacting protein: regulation and function in the pancreatic β-cell
Guerre-Millo Adipose tissue and adipokines: for better or worse
US7850976B2 (en) Insulin resistance improving agents
Ro et al. Adipocyte enhancer‐binding protein 1 modulates adiposity and energy homeostasis
Farhan et al. A review on the role of novel adipokine Isthmin-1 and Subfatin in human type 2 diabetes mellitus
EP1701978B1 (de) Verwendung von löslichem T-Cadherin zur Behandlung von Stoffwechselkrankheiten
Nakao et al. Translational research of novel hormones: lessons from animal models and rare human diseases for common human diseases
KR102204521B1 (ko) Ｐｒｏｇｒａｎｕｌｉｎ 단백질을 포함하는 간질환의 예방 또는 치료용 조성물
CN117899223A (zh) 以nup35基因和或以nup35蛋白作为作用靶点的物质的应用及组合物
WO2018191599A1 (en) Brown fat-selective adipokines
KR101656931B1 (ko) Idh2를 유효성분으로 함유하는 비만 또는 비만 매개 대사성 질환의 예방 또는 치료용 조성물
JPWO2005097171A1 (ja) 抗肥満薬
JP4273307B2 (ja) メタボリック・シンドローム非ヒトモデル動物
TW202146040A (zh) 脂質代謝之動物模型及治療高脂血症或高脂血症相關疾病的方法
Harada et al. Transgenic mouse and gene therapy
Funahashi et al. Adipocytokines
JP2009108091A (ja) メタボリック・シンドローム非ヒトモデル動物
CA2542142A1 (en) Methods and compositions using adiponectin for treatment of cardiac disorders and for stimulation of angiogenesis
CN117815363A (zh) Star-PAP在制备提高脂肪胰岛素敏感性药物中的应用
JP2007209214A (ja) インスリン分泌誘導剤、インスリン分泌誘導組成物及びその製造方法、遺伝子治療用ウイルスベクター
JPH11185A (ja) Ａｔｇ−１１２０（ａｉｆ−１−デルタ）、ａｉｆ−１／ｒｃ−９の新規スプライス変種
WO2006011491A1 (ja) プラスミドベクター及びトランスジェニック動物並びに医薬のスクリーニング方法及び医薬
Miyamoto et al. Anti-Inflammatory Effect of Cholecystokinin
Ikegami pressed (data not shown). Interestingly, only the signals suggesting that IRS-1 co-localized with these p85 foci in observed in an immunofluorescence study using antibodies response to insulin. Though we cannot rule out the possi-against IRS-1 corresponded to with these foci (Fig. 2h), bility that the p85-IRS-1 complex contains other unex

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20180528